Search

Your search keyword '"van Kuilenburg, André B.P."' showing total 42 results

Search Constraints

Start Over You searched for: Author "van Kuilenburg, André B.P." Remove constraint Author: "van Kuilenburg, André B.P." Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
42 results on '"van Kuilenburg, André B.P."'

Search Results

1. CIAO1 and MMS19 deficiency: A lethal neurodegenerative phenotype caused by cytosolic Fe-S cluster protein assembly disorders

2. Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare DPYD Variants

6. β-Ureidopropionase deficiency due to novel and rare UPB1 mutations affecting pre-mRNA splicing and protein structural integrity and catalytic activity

9. Deficiency of perforin and hCNT1, a novel inborn error of pyrimidine metabolism, associated with a rapidly developing lethal phenotype due to multi-organ failure

11. A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapy

12. List of Contributors

23. Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil:A Note of Caution Based on a Large Prospective Clinical Study

24. Children with atopic dermatitis show increased activity of β‐glucocerebrosidase and stratum corneum levels of glucosylcholesterol that are strongly related to the local cytokine milieu

26. Purine and Pyrimidine Metabolism

27. Co-therapy with S-adenosylmethionine and nicotinamide riboside improves t-cell survival and function in Arts Syndrome (PRPS1 deficiency)

29. Predicting the Development of Anti-Drug Antibodies against Recombinant alpha-Galactosidase A in Male Patients with Classical Fabry Disease

30. Glutaminase Deficiency Caused by Short Tandem Repeat Expansion in GLS

32. Liposome-targeted recombinant human acid sphingomyelinase: Production, formulation, and in vitro evaluation

33. A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapy

34. Genome sequencing reveals a novel genetic mechanism underlying dihydropyrimidine dehydrogenase deficiency: A novel missense variant c.1700G>A and a large intragenic inversion in DPYD spanning intron 8 to intron 12

35. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer : a prospective safety analysis

36. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

37. Diagnostic and therapeutic strategies for fluoropyrimidine treatment of patients carrying multiple DPYD variants

38. Treatment Algorithm for Homozygous or Compound Heterozygous DPYD Variant Allele Carriers With Low-Dose Capecitabine

41. Catecholamines profiles at diagnosis: Increased diagnostic sensitivity and correlation with biological and clinical features in neuroblastoma patients

42. CIAO1and MMS19deficiency: a lethal neurodegenerative phenotype caused by cytosolic Fe-S cluster protein assembly disorders

Catalog

Books, media, physical & digital resources